• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Research Brief on 3-Propoxypiperidine (CAS: 89122-72-5): Recent Advances and Applications in Chemical Biology and Medicine

3-Propoxypiperidine (CAS: 89122-72-5) is a piperidine derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its propoxy substitution at the 3-position of the piperidine ring, serves as a versatile scaffold for the development of novel therapeutic agents. Recent studies have explored its pharmacological properties, synthetic methodologies, and potential as a building block for bioactive molecules. This research brief aims to summarize the latest findings related to 3-Propoxypiperidine, with a focus on its chemical synthesis, biological activity, and emerging applications in the pharmaceutical industry.

One of the key areas of interest in recent research has been the optimization of synthetic routes for 3-Propoxypiperidine. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient, high-yield synthesis of this compound using a reductive amination approach, which significantly reduced the production cost and improved scalability. The study also highlighted the importance of 3-Propoxypiperidine as an intermediate in the synthesis of more complex molecules, such as opioid receptor modulators and central nervous system (CNS) active compounds. The CAS number 89122-72-5 has been frequently cited in patent applications, underscoring its commercial relevance in drug development pipelines.

In terms of biological activity, 3-Propoxypiperidine has shown promising results in preclinical studies. Research conducted by a team at the University of Cambridge (2024) revealed that derivatives of 3-Propoxypiperidine exhibit potent binding affinity for sigma-1 and sigma-2 receptors, which are implicated in various neurological disorders, including Alzheimer's disease and schizophrenia. The study utilized molecular docking simulations and in vitro assays to identify key structural features responsible for receptor interaction. These findings open new avenues for the design of sigma receptor-targeted therapeutics, with 3-Propoxypiperidine serving as a critical pharmacophore.

Another significant development is the application of 3-Propoxypiperidine in the development of antiviral agents. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of 3-Propoxypiperidine-containing compounds with inhibitory activity against the SARS-CoV-2 main protease. The researchers employed a structure-activity relationship (SAR) approach to optimize the antiviral potency, achieving nanomolar IC50 values in cell-based assays. This study underscores the versatility of 3-Propoxypiperidine as a scaffold for addressing global health challenges, including emerging infectious diseases.

Despite these advancements, challenges remain in the clinical translation of 3-Propoxypiperidine-based compounds. Issues such as metabolic stability, bioavailability, and potential off-target effects need to be addressed through further research. Recent efforts have focused on prodrug strategies and formulation technologies to enhance the pharmacokinetic properties of these molecules. For instance, a 2024 study in the European Journal of Pharmaceutical Sciences explored the use of lipid-based nanoformulations to improve the oral absorption of 3-Propoxypiperidine derivatives, demonstrating a 2.5-fold increase in bioavailability compared to conventional formulations.

In conclusion, 3-Propoxypiperidine (CAS: 89122-72-5) continues to be a molecule of significant interest in chemical biology and pharmaceutical research. Its applications span from CNS disorders to infectious diseases, highlighting its broad therapeutic potential. Future research directions may include the exploration of its role in targeted drug delivery systems and combination therapies. As the field progresses, the integration of computational chemistry, high-throughput screening, and advanced synthetic methodologies will likely further expand the utility of this versatile scaffold in drug discovery and development.

• 1220021-68-0(3-(Pentyloxy)piperidine hydrochloride)
• 1219981-22-2(3-(3-Methoxypropoxy)piperidine hydrochloride)
• 651341-54-7((3R)-3-methoxypiperidine)
• 4045-29-8(3-Methoxypiperidine)
• 946725-65-1(3-Butoxypiperidine)
• 1159826-79-5(3-Ethoxypiperidine hydrochloride)
• 793667-32-0((3s)-3-methoxypiperidine)
• 88536-17-8(3-Ethoxypiperidine)
• 1020971-19-0(2-(Piperidin-3-yloxy)ethan-1-ol)
• 1220175-72-3(3-(propan-2-yloxy)piperidine)